New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Eli Lilly and Company

LLY

Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.

Revenue
+38.6%
EPS
+16.3%
Free cash flow
+21.8%
Total debt
+15.0%

Quarter to September 2026, against a year earlier

1,351.35 0.30 −0.02%
Market cap
$1.27T
P/E
43.9×
Fwd P/E FY26e
42.2×
Dividend yield
0.51%
F-score
7/9
ROIC
26.4%
Net debt / EBITDA
1.2×
Payout ratio
0.2×

Eli Lilly and Company 10-Q filed Oct 29, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 11:35 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 5, 2026: 2 removed · 22 modified; 8 with only figures updated; 1 moved without change

  1. Modified · Financial Results

    Net income and earnings per share for the three months ended June 30, 2026 increased primarily due to higher gross margin, partially offset by higher acquired IPR&D charges, asset impairment, restructuring, and other special charges, and marketing, selling, and administrative expenses. Net income and earnings per share for the six nine months ended JuneSeptember 30, 2026 increased primarily due to higher gross margin, partially offset by higher acquired IPR&D charges, research and development expenses, and marketing, selling, and administrative expenses.

23 more changes in this Item, word by word, in Powerpack.